Novotech appointed Dr. Anand Tharmaratnam as Chairman and Chief Executive Officer. Dr. Tharmaratnam’s elevation represents a significant leadership milestone for Novotech as it enters its next phase of global expansion and strategic growth.

With over three decades of leadership experience in the global Contract Research Organisation (CRO) and life sciences industry. He has also served as Chairman of Novotech’s Board, IQVIA, Saama, Holmusk, ObvioHealth, and TPG. His prior roles encompassed oversight of clinical operations, market access strategies, and cross-regional business transformation initiatives across Asia Pacific and beyond.

An accomplished physician by training, Dr. Tharmaratnam holds a Doctor of Medicine (MD) degree from UCL and completed specialised training in anaesthesia and critical care in the United Kingdom. He has cultivated deep clinical insights and strategic leadership capabilities, amassing nearly 30 years of professional experience in healthcare and clinical research.

In his new role as CEO, Dr. Tharmaratnam will focus on strengthening Novotech’s global footprint, enhancing scientific capabilities, and advancing operational excellence to meet the evolving needs of biotechnology and pharmaceutical partners worldwide. This appointment will advance the company’s long-term mission to accelerate innovation in clinical research and deliver high-impact outcomes for clients across key markets.